Risk 76 items
Studies
- Formula-based Lp(a)-C estimates overstate cholesterol content and understate true LDL-C, direct-assay study of 278 patients (J Clin Lipidol 2026)
- Lp(a)-lowering therapy would be cost-effective at up to £5,500 a year in secondary prevention, UK Biobank-based health technology assessment (Atherosclerosis 2026)
- Lp(a) raises coronary event risk mainly by driving plaque burden, SCAPIS cohort of 28,529 (JACC Cardiovasc Imaging 2026)
- Lp(a) above 46.8 nmol/L, below current guideline thresholds, still raises MACE risk 20% in statin-treated patients, UK Biobank cohort of 17,376 (Eur J Prev Cardiol 2026)
- Lp(a) testing is linked to more aggressive lipid treatment and better LDL-C goal attainment, Veterans Affairs cohort of 6.9 million (J Am Heart Assoc 2026)
- High-risk Lp(a) accelerates coronary plaque progression across CCTA, IVUS and OCT, meta-analysis of 19,822 (Atherosclerosis 2026)
- High Lp(a) and high BMI jointly maximize ASCVD risk, Danish and UK Biobank cohorts of 512,687 (Eur J Prev Cardiol 2026)
- Genetic Lp(a) raises large-artery stroke risk 23% but not small vessel stroke, Mendelian randomisation of 343,681 (J Am Heart Assoc 2026)
- High Lp(a) erases the mortality benefit of high HDL-C, especially in men, cohort of 97,396 (Coron Artery Dis 2026)
- MASLD blunts Lp(a) yet MASLD with elevated Lp(a) doubles cardiovascular risk, MESA cohort (Metabolism 2026)
- Lp(a) and a 43-variant genetic risk score predict sudden cardiac death in older men with high triglycerides, UK Biobank cohort of 323,666 (Mayo Clin Proc 2026)
- Elevated Lp(a) and insulin resistance jointly double cardiovascular mortality risk in MASLD, UK Biobank analysis of 101,348 (Cardiovasc Diabetol 2026)
- MASLD lowers Lp(a) in men and postmenopausal women but not premenopausal women, SHIP and UK Biobank cohorts (Cardiovasc Diabetol 2026)
- Lp(a) is causally linked to aortic aneurysm risk by Mendelian randomisation, UK Biobank cohort of 312,332 (J Clin Lipidol 2026)
- Lp(a) of 30 mg/dL or more predicts CKD progression and cardiovascular death, nationwide Chinese cohort study (J Clin Lipidol 2026)
- Obstructive sleep apnea raises cardiovascular risk only in ACS patients with above-median Lp(a), OSA-ACS cohort of 1137 (Sleep 2026)
- Phenotypic clustering splits high-Lp(a) patients into distinct cardiovascular risk groups, cohort of 2,355 (Sci Rep 2026)
- Elevated Lp(a) raises PAD prevalence (OR 1.81) and triples repeat revascularisation after limb procedures (J Vasc Surg 2026)
- Genetic evidence suggests Lp(a) lowering is unlikely to raise pregnancy-complication risk, Mendelian randomisation preprint (medRxiv 2026)
- IL-6 receptor signalling and Lp(a) independently lower cardiovascular risk, Mendelian randomisation study (JACC Basic Transl Sci 2026)
- Lp(a) above 58 mg/dL overestimates LDL-C by 10% or more across all major formulas, study of 3,923 (Clin Lab 2026)
- Lp(a) shifts across pregnancy and menopause and demands sex-specific attention, review of women's cardiovascular health (JACC Adv 2026)
- IL-6 modifies whether Lp(a) predicts cardiovascular events, UK Biobank cohort of 34,092 (Atherosclerosis 2026)
- High Lp(a) tracks with advanced coronary calcium and carotid atherosclerosis in asymptomatic patients, cohort of 3,697 (Nutr Metab Cardiovasc Dis 2026)
- Elevated Lp(a) is linked to mitral annular calcification but not regurgitation, propensity-matched study of 66,292 pairs (J Clin Lipidol 2026)
- Joint control of LDL-C, Lp(a) and CRP erases the excess cardiovascular risk of steatotic liver disease in a 291,995-person UK Biobank cohort (Nutr Metab Cardiovasc Dis 2026)
- Elevated Lp(a) raises repeat revascularisation risk after PCI, meta-analysis of eighteen studies (Acta Cardiol 2026)
- Lp(a) of 50 mg/dl or more raises recurrent MACE risk 82.6% in very young acute coronary syndrome survivors, STudy of eArly Myocardial INfArction registry (Coron Artery Dis 2026)
- Lp(a) causally raises abdominal aortic aneurysm risk, UK Biobank analysis of 1,026 cases (JACC Basic Transl Sci 2026)
- Lp(a) and LDL-C synergistically raise MI risk, amplified by polygenic risk score, UK Biobank cohort of 346,751 (Am J Cardiol 2026)
- Lp(a) drives premature cardiovascular disease even at goal LDL-C, review calls for universal testing and cascade screening (Eur J Prev Cardiol 2026)
- Lp(a) and homocysteine each independently stiffen arteries in treated hypertension, 366-patient cross-sectional study (J Clin Med 2026)
- Lp(a) drives worse outcomes after PCI and progression of aortic stenosis before TAVI, review for interventional cardiologists (J Clin Med 2026)
- Lp(a) is roughly twice as prevalent in coronary heart disease patients as in the Czech general population, 2001-subject study (Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2026)
- Lp(a) is not clinically linked to atrial fibrillation, meta-analysis of 16 observational and 7 Mendelian randomisation studies (J Clin Lipidol 2026)
- Elevated Lp(a) raises cardiovascular death risk 51% after successful CTO-PCI, 1509-patient cohort (J Cardiovasc Dev Dis 2026)
- Elevated Lp(a) is linked to 3.5-times higher odds of treatment intensification, 530-patient academic health-center study (J Clin Lipidol 2026)
- SGLT2 inhibitors slow CKD progression and raise Lp(a) normalisation in patients with elevated Lp(a), TriNetX cohort of 2,813 matched pairs (J Cardiovasc Pharmacol 2026)
- Lp(a) of 149 nmol/L or more flags greater anatomic coronary disease burden, angiography registry of 2230 (Cardiovasc Revasc Med 2026)
- Elevated Lp(a) is not linked to dementia risk in a 151,117-patient propensity-matched real-world cohort (Eur J Intern Med 2026)
- LPA gene variants explain 28% of Lp(a) variability but not coronary anatomy in chronic coronary syndrome, 390-patient study (J Clin Lipidol 2026)
- CKD enriches Lp(a) with triacylglycerols, diacylglycerols and oxidised phospholipids, 54-patient lipidomic study (J Clin Lipidol 2026)
- Gulf countries expert consensus endorses routine Lp(a) testing in cardiovascular risk assessment (Atheroscler Plus 2026)
- Lp(a) above 18.8 mg/dL independently predicts coronary plaque vulnerability on IVUS, 292-patient study (J Atheroscler Thromb 2026)
- Elevated Lp(a) raises cardiovascular risk mainly when homocysteine is also high, coronary disease cohort of 530 (BMC Cardiovasc Disord 2026)
- Patients find Lp(a) testing acceptable and motivating despite no approved therapy, INTERASPIRE survey across seven countries (Eur J Cardiovasc Nurs 2026)
- Lp(a) lowers type 2 diabetes risk only in severe prediabetes, UK Biobank analysis (Diabetes Metab Syndr 2026)
- Lp(a) is higher in Japanese coronary disease patients than controls, comparative study of 3,710 (Circ Rep 2026)
- Lp(a) drives residual cardiovascular risk after ACS, with RNA therapies pending outcome-trial confirmation, review (J Clin Med 2026)
- Lp(a) and triglyceride-rich particles are several-fold more atherogenic than LDL per particle, review on combination therapy (Pharmacol Ther 2026)
- Lp(a) testing rose from 3,052 to 8,425 orders a year across a US health system, cohort of 450,412 (Am J Prev Cardiol 2026)
- LPA risk alleles rs3798220 and rs10455872 raise coronary disease odds up to 75%, meta-analysis of 55,647 (Am J Med Sci 2026)
- LDL-C in the normal range cannot rule out very high Lp(a), Danish cohort of 1,346 (Lipids 2026)
- Smoking is inversely linked to Lp(a) in a Korean cohort of 146,129 (J Lipid Atheroscler 2026)
- Falling Lp(a) in MASLD reflects liver damage, not falling cardiovascular risk (Curr Cardiol Rep 2026)
- Elevated Lp(a) raises cardiovascular event odds (OR 5.3) in people living with HIV, 186-patient cohort (Clin Med Lond 2026)
- Common vitamin and supplement use does not shift Lp(a) over time, UK Biobank analysis of 12,109 (Lipids Health Dis 2026)
- Lp(a) does not predict long-term cardiometabolic risk in healthy women despite its lipid links, 387-woman cohort (Metabolites 2026)
- Lp(a) and peripheral artery disease independently stiffen arteries in hypertension, 366-patient cohort (J Clin Hypertens Greenwich 2026)
- Lp(a) has no prognostic significance in coronary artery spasm without stenosis, 1,373-patient study (Heart Vessels 2026)
- Lp(a) does not predict bioprosthetic aortic valve degeneration, unlike native valve disease, cohort of 389 (Clin Res Cardiol 2026)
- Monocyte-to-HDL and lymphocyte-to-monocyte ratios track with high Lp(a) in healthy adults, diagnostic accuracy study (Acta Cardiol Sin 2026)
- Elevated Lp(a) adds $253 million in indirect costs over 5 years in a US Markov simulation (Am J Prev Cardiol 2026)
- Lp(a) does not correlate with blood pressure in essential hypertension despite comorbidity differences, cohort of 230 (High Blood Press Cardiovasc Prev 2026)
- Elevated Lp(a) does not predict organ damage or cardiovascular events in a low-risk primary prevention cohort of 747 (High Blood Press Cardiovasc Prev 2026)
- High Lp(a) may worsen long-term survival after TAVI despite similar 12-month MACCE, prospective cohort of 82 (Pol Arch Intern Med 2026)
- Lp(a) is unrelated to body composition, unlike HDL-C and triglycerides, high-risk cohort of 207 (Adv Med Sci 2026)
- Elevated Lp(a) tracks with peripheral artery disease in MASLD, cross-sectional study of 468 (BMC Cardiovasc Disord 2026)
- Elevated Lp(a) raises VLDL particle number, not composition, in normotriglyceridemic adults, study of 70 (Int J Mol Sci 2026)
- Lp(a) rises with chronic kidney disease and independently predicts cardiovascular risk in CKD, review of emerging therapies (Clin J Am Soc Nephrol 2026)
- Lp(a) above 105 nmol/L flags cardiovascular risk in chronic kidney disease, but no targeted therapy yet exists, review (J Nephrol 2026)
- Lp(a) is not linked to cardiac allograft vasculopathy after heart transplant, 271-patient single-center cohort (J Clin Lipidol 2026)
- Higher vitamin D is linked to lower Lp(a) in elite athletes, cross-sectional study of 773 (Nutrients 2026)
